About / Overview
ImmusanT is leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to discover, develop and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases such as celiac disease, Type-1 diabetes and other human leukocyte antigen (HLA)-linked diseases. ImmusanT's lead product, Nexvax2®, selectively modifies the immune response to gluten and improves the tolerability of gluten during controlled challenge studies and in parallel leads to a marked reduction of the biomarkers of inflammation.
ImmusanT is also using its technology and deep understanding of the immune system to develop new diagnostics that have the potential to provide highly specific and highly accurate diagnoses of auto-immune diseases. Our first diagnostic – GC2™ – is being developed to diagnose celiac disease through a simple in vitro blood test designed to measure T-cell markers.